Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers



Status:Recruiting
Conditions:Other Indications, Cardiology, Cardiology, Gastrointestinal
Therapuetic Areas:Cardiology / Vascular Diseases, Gastroenterology, Other
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:November 2016
End Date:November 2019
Contact:Raphael Yaakov, MS
Email:ryaakov@serenagroups.com
Phone:6179455225

Use our guide to learn which trials are right for you!

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of
chronic venous insufficiency ulcers has been established. This study is designed to determine
the most efficient method of treatment.

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the
effectiveness of TR 987 gel. It is a two-arm, design: One group will receive twice-weekly
applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks. The other group
will receive twice-weekly applications of placebo gel base plus SoC for the same period of
time. After 4 weeks, both groups will receive once weekly applications of their assigned
treatment for the remaining 8 weeks of the trial. The Standard of Care therapy in this study
is multi-layer compression therapy.

Inclusion Criteria:

1. Subject is at least 18 years old

2. Female subjects are not pregnant or breastfeeding.

3. Study ulcer has been present for at least one month and has undergone more than 2
weeks, but less than 12 months of continuous high-strength compression with less than
40% healing.

4. Study ulcer is a minimum of 2.0 cm2 and a maximum of 20.0 cm2, extending through the
full thickness of the skin, but not down to muscle, tendon, or bone at the
randomization visit.

5. Study ulcer has a clean, granulating base with minimal adherent slough at the
randomization visit.

6. If more than one ulcer is present on the same leg, they must be more than 2 cm apart
and only the larger ulcer will be included in the study.

7. Adequate arterial flow, as measured by an Ankle Brachial Pressure Index (ABI) of
greater than 0.75. (Calculations will be made using measurements from both posterior
tibial and dorsalis pedis arteries, as well as both arms) and/or Skin Perfusion
Pressure (SPP) >30.

8. Subject understands and is willing to participate in the clinical study and can comply
with weekly visits and the follow-up regimen.

9. Patient understands and is willing to participate in the clinical study and can comply
with weekly visits and the follow-up regimen.

10. Patient has read and signed the IRB/IEC approved Informed Consent Form before
screening procedures are undertaken.

Exclusion Criteria:

1. Study ulcer deemed by the Investigator to be caused by a medical condition other than
venous insufficiency.

2. Study ulcer exhibits clinical signs and symptoms of infection.

3. Study ulcer requires enzymatic debridement during the study.

4. Study ulcer has undergone 12 or more months of continuous high-strength compression
therapy over its duration.

5. Study ulcer is less than 2.0 cm2 or greater than 20.0 cm2.

6. Study ulcer extends more than 50% below the malleolus.

7. Study ulcer is treated with a topical antibiotic during the screening phase.

8. Study ulcer has been treated with tissue engineered material (e.g., Apligraf® or
Dermagraft®) or other scaffold materials (e.g., Oasis or Matristem) within 30 days
prior to the TV1 Randomization visit.

9. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the
course of the trial.

10. History of radiation at the study ulcer site.

11. Study ulcer decreases in area by 30% or more during the 14 days screening period.

12. Subjects who are unable to understand the aims and objectives of the trial or has a
known history of poor adherence with medical treatment.

13. Presence of any condition(s) that seriously compromises the subject's ability to
complete this study.

14. All females of childbearing potential who are not using a highly effective method of
birth control (failure rate less than 1% per year), such implants, injectables,
combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner.
We found this trial at
12
sites
York, Pennsylvania 17403
Principal Investigator: Maria Kasper, DPM
Phone: 717-757-3537
?
mi
from
York, PA
Click here to add this to my saved trials
Browns Mills, New Jersey 08015
Principal Investigator: Vikram Palkar, DO
?
mi
from
Browns Mills, NJ
Click here to add this to my saved trials
Chambersburg, Pennsylvania 17201
?
mi
from
Chambersburg, PA
Click here to add this to my saved trials
Cleveland, Ohio 44103
Principal Investigator: Windy Cole, DPM
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Ford City, Pennsylvania 16226
?
mi
from
Ford City, PA
Click here to add this to my saved trials
Kittanning, Pennsylvania 16201
Phone: 724-543-8893
?
mi
from
Kittanning, PA
Click here to add this to my saved trials
Los Angeles, California 90063
Principal Investigator: Gabriel Halperin, DPM
Phone: 323-264-6157
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami Lakes, Florida 33016
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
North Miami Beach, Florida 33013
Principal Investigator: Robert Snyder, DPM
?
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Pembroke Pines, Florida 33027
Principal Investigator: Neal Bullock, DPM
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15222
Principal Investigator: Bryan Doner, DO
Phone: 412-212-0123
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials